
Report ID: SQMIG35B2227
Skyquest Technology's expert advisors continuously track and analyze the latest developments and updates related to insulin syringes market. Our team of analysts stay abreast of all the recent news stories shaping the industry including new product launches by major companies, strategic partnerships, M&As, Patent filings and industry and regulatory developments.
REQUEST FOR SAMPLE
Global Insulin Syringes Market size was valued at USD 1.77 Billion in 2023 poised to grow from USD 1.84 Billion in 2024 to USD 2.56 Billion by 2032, growing at a CAGR of 4.20% in the forecast period (2025-2032).
The global insulin syringes market outlook is highly competitive, with key players like Becton Dickinson, Terumo Corporation, Nipro Corporation, and Owen Mumford leading innovation. They concentrate on product differentiation by innovative needle technology, safety and ergonomic designs. Becton Dickinson puts a lot of emphasis on strategic acquisitions and building up its global distributor network, while Terumo heavily invests in the research and development of ultra-thin needles. Collaborative partnerships and compliance with regulations are still key strategies to build market strength globally. 'Becton Dickinson (USA)', 'Terumo Corporation (Japan)', 'Nipro Corporation (Japan)', 'Owen Mumford (UK)', 'Ypsomed Holding AG (Switzerland)', 'Smiths Medical (USA)', 'B. Braun Melsungen AG (Germany)', 'HMD Medical (India)', 'Owen Mumford Ltd (UK)', 'Medline Industries (USA)', 'Shandong Weigao Group Medical Polymer Company (China)', 'Jiangsu Kangjian Medical Equipment Co., Ltd. (China)', 'Lifecare Innovations (India)', 'Owen Mumford Ltd (UK)', 'Henke-Sass, Wolf GmbH (Germany)'
The growing geriatric population globally is at higher risk for diabetes, and therefore, there is increased insulin consumption. With rising cases of age-induced diabetes, demand for insulin syringes increases consistently, propelling market growth owing to the necessity of proper and frequent insulin administration.
Rising Demand for Miniaturized Syringes: There is a tendency towards smaller insulin syringes, i.e., 0.5 ml, providing better dosing accuracy and comfort. This is triggered by higher incidence of pediatric patients and Type 1 diabetics, who urge manufacturers to develop smaller, convenient syringues that increase patient compliance.
How does the Prevalence of Diabetes in North America Impact Syringe Demand?
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35B2227
[email protected]
USA +1 351-333-4748